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ABSTRACT
The synthetic vasopressin analogue, desmopressin (dDAVP), has been
shown to influence membrane transport of melphalan in murine L5178Y
lymphoblasts. Accordingly, the effect of dDAVP on the cytocidal activity
of melphalan in LS178Y cells was evaluated. dDAVP did not affect the
cytocidal activity of melphalan in these cells, but significantly affected
the cloning efficiency of stationary phase or slowly dividing LSI78Y cells
over a range of concentrations. In particular, stationary phase cells
showed an increase in cloning efficiency from 4.3 Â±0.5% in control cells
to 7.0 Â±0.3% in cells treated with 25 nM dDAVP (P < 0.001), whereas
cells doubling every 26 h showed an increase from 10.8 Â±1.2% in control
cells to 21.0 Â±2.0% in cells treated with 150 nM dDAVP (P < 0.001).
This phenomenon was associated with significant elevations of l,2|'ll|
diacylglycerol after incubation with dDAVP for 9 min (P < 0.01) and of
total pHjdiacylglycerols after incubation for both 3 min (P < 0.05) and
9 min (/' < 0.02). Within 10 s of treatment with 100 nM dDAVP, there
was a marked decrease in the levels of inositol 1,4,5-trisphosphate and
inositol 1-phosphate, but subsequently no change was observed for up to
9 min after treatment. We postulate that the increase of diacylglycerol
content produced by dDAVP might be primarily from a phosphatidyl-
choline source and that the growth-promoting activity of desmopressin
may be a consequence of activation of protein kinase C.
INTRODUCTION
The synthetic vasopressin analogue, dDAVP4 or desmopres
sin, has been shown to influence a wide range of cell membrane-
related events. Recently, Goldenberg et al. reported on modu
lation of membrane transport of alkylating agents and amino
acids by dDAVP (1). dDAVP stimulated melphalan uptake,
inhibited uptake of nitrogen mustard, and had no effect on the
uptake of cyclophosphamide. dDAVP is also recognized as the
drug of choice in the treatment of diabetes insipidus and in
other situations where an antidiuretic effect is useful, and in
the treatment of bleeding disorders (2).
Vasopressin, the native counterpart of dDAVP, has also been
shown to be a potent mitogen for quiescent cultures of Swiss
3T3 cells (3). Vasopressin induces phosphatidylinositol break
down (4) in several cell lines such as smooth muscle A-10 and
in rat hepatocytes (5,6) and also stimulates the efflux of calcium
from an intracellular pool (7). The action of vasopressin and
other growth factors, e.g., platelet-derived growth factor and
bombesin, on Swiss 3T3 cells results in an increased formation
of DAG (8) and IP3 (4). The latter is likely to function as a
second messenger to mediate the calcium-mobilizing action of
growth factors. The hydrolysis of PIP: induced by growth
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factors is known to result in the activation of two signal path
ways which may regulate key ionic events responsible for cell
proliferation. Changes in pH may be controlled through DAG,
whereas calcium levels are regulated by IPa.
The present study was undertaken to determine if the effect
of dDAVP on transport could be exploited therapeutically to
enhance the cytocidal activity of melphalan against L5178Y
lymphoblasts. dDAVP treatment was found to increase cloning
efficiency of these cells, so the investigation was expanded to
elucidate the mechanism of this apparent growth-promoting
activity.
MATERIALS AND METHODS
Drugs and Chemicals. Melphalan, p-di(2-chloroethyl)amino-L-phen-
ylalanine, was provided by Dr. J. R. MacDougall, Burroughs Wellcome
and Co. (Canada), Ltd., Montreal, Quebec. dDAVP was obtained from
Richmond Pharmaceuticals, Inc., Richmond Hill. Ontario, Canada.[5,6,8,9,1 l,12,14,15-3H]Arachidonic acid in ethanol (94.5 Ci/mmol)
was obtained from New England Nuclear, Boston, MA. Unlabeled
arachidonic acid (5,8,11,14-eicosatetraenoate), 1,2- and 1,3-diacyl-sn-
glycerol, and pig liver triglycÃ©rideswere obtained from Serdary Re
search Laboratories, Inc., London, Ontario, Canada. 2-m>>0-[:>H]Inosi-
tol (specific activity, 15 Ci/mmol) was purchased from American Ra-
diolabelled Chemicals, Inc., St. Louis, MO.
Cytotoxic Activity of Melphalan in the Presence and Absence of
dDAVP. The sensitivity of murine L5178Y lymphoblasts to melphalan
in the presence and absence of dDAVP was determined using the
clonogenic assay of Chu and Fisher (9). Exponential phase cells at a
concentration of 2 to 3 x 10*cells/ml were treated with melphalan for
15 min at 37Â°Cin DPBS after treatment with either 100 nM dDAVP
or 0.85% NaCl solution as control for IO min. The cloning efficiency
of treated cells was determined at each drug concentration, and the
surviving cell fraction was calculated. Linear regression analysis of the
dose-survival curves was performed, the regression equation being in
the form, log,y = mx + b, where y is the surviving cell fraction, x is the
dose of drug, m is the slope of the regression line, and b is the y-
intercept. Do, the dose of drug reducing survival to \/e, i.e., 37% of the
initial cell population, was derived from the negative reciprocal of the
slope of the regression line as described previously (10). Statistical
analysis of the dose-survival curves and intercepts was performed by a
t test comparing the significance of the difference of slopes.
Assay of Growth-promoting Activity. The growth-promoting effect of
dDAVP on murine L5178Y lymphoblasts was determined in Fisher's
medium containing 15 to 20% horse serum using the clonogenic assay
of Chu and Fisher (9). Stationary phase cells and cells with doubling
times ranging from 12 to 26 h, each at a concentration of 2.5 to 3.5 x
10s cells/ml, were treated with dDAVP or 0.85% NaCl solution as
control for 10 min at 37Â°Cin DPBS, and cloning efficiency was
determined. The growth-promoting effect of dDAVP on exponential
phase P388 leukemia cells was also determined. Statistical analysis of
the difference in cloning efficiency of control and dDAVP-treated cells
was determined using unpaired t tests.
DAG Assay. [3H]Arachidonic acid was added to exponentially mul
tiplying L5178Y cells at 2 x 10*cells/ml in Fisher's medium containing
10% horse serum. After incubation for 44 h the cells, which were
doubling approximately every 27 h, were centrifuged at 1000 rpm for
5 min, washed, and Â«suspended in DPBS at 3.0 to 3.5 x 10' cells/ml.
Cell suspensions of 18.2 ml were treated with either 100 nM dDAVP
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or 0.85% NaCI solution as control for 10 min at 37Â°C.Incubation was
terminated by addition of 30 ml of ice-cold DPBS and centrifugation
at 1000 rpm, and the supernatant was discarded. The cell pellet was
resuspended in 3 ml of ethyl acetate, agitated for l S s, and centrifuged,
and the supernatant was collected for TLC (11). One additional extrac
tion was performed with 3 ml of ethyl acetate, and two with 3 ml of
ethyl acetate after addition of 20 Â¿ilof l N HC1. The solvent was
evaporated under N2 at 37Â°C;5 n\ of ethyl acetate were added to the
cell extracts; and unlabeled arachidonic acid, 1,2- and 1,3-DAG, and
pig liver triglycÃ©rideswere added as standards. The cell extracts and
standards were applied to a "Baker" 7000-4 Si 250 TLC plate (J. B.
Baker Co.) which had been activated at 100Â°Cfor 60 min. Lipid
migration look place in a solvent system of benzene:diethyl
etherethanohacetic acid (50:40:2:0.2) (12). After drying, the lipids were
localized by brief exposure to iodine vapor, and their mobility was
compared with that of standards on the same plate. Radioactivity was
counted using a System 200 imaging scanner (Bioscan, Inc.) coupled
to an IBM-PC XT.
Assay of Inositol Phosphates. Murine L5178Y lymphocytes were
usually cultured in Fisher's medium containing 15% horse serum; after
transfer to Fisher's medium containing 7.5% horse serum, the doubling
time of these cells was prolonged from 12 to approximately 22 h. Cells
were incubated in this suboptimal medium for 32 h, at which point
/w>>o-['H]inositol(0.4 nC\/m\) was added, and the cells were incubated
for an additional 16 h without changing medium. At the end of 48-h
incubation, cells were harvested, washed, and suspended in DPBS.
To study the effect of dDAVP on inositol phosphates, cells were
incubated at 37'C with either 100 nM dDAVP or 0.85% NaCI solution
as control. Aliquots of 500 iÂ¡\of incubation mixture were removed at 0
and 10 s and at 3 and 9 min and immediately placed in 1.88 ml of
chloroform:methanol:HCl (100:200:2). To this mixture, 0.6 ml of
chloroform were added, followed by 0.6 ml of water. Tubes were
centrifuged briefly at 1000 rpm, and the upper aqueous layer was
collected and applied on a 2.0ml column of Bio-Rex (formate form).
The radioactive phosphate esters were eluted sequentially by using 5
HIMdisodium tetraborate/60 HIMsodium formate (for glycophosphoi-
nositol), 0.1 M formic acid/0.2 M ammonium formate (for IP), 0.1 M
formic acid/0.4 Mammonium formate (for II'.), and 0.1 M formic acid/
1.0 M ammonium formate (for UM as described by Berridge et al.. (13).
RESULTS
Dose-Survival Curves of Murine LSI78Y Lymphoblasts
Treated with Melphalan in the Presence or Absence of dDAVP.
Dose-survival curves of murine L5178Y lymphoblasts treated
with melphalan in the presence or absence of dDAVP were
obtained. The Da (mean Â±SE) for LSI78Y cells treated with
melphalan alone was 0.7S Â±0.04 UM.and that for cells treated
with melphalan and dDAVP was 0.73 Â±0.02 ^M; there was no
significant difference between the slopes or intercepts of these
curves.
Effect of dDAVP and Vasopressin on the Cloning Efficiency
of Murine LS178Y Lymphoblasts and P388 Leukemia Cells.
The effect of dDAVP on the cloning efficiency of L5178Y cells
with varying proliferative rates is shown in Table 1. dDAVP at
a concentration range of 25 to 225 nM significantly augmented
the cloning efficiency of stationary phase cells or cells dividing
every 26 h, whereas exponential phase cells and those with a
doubling time of 16 h showed significant augmentation of
cloning efficiency only after treatment with 150 nM dDAVP.
Vasopressin also enhanced the cloning efficiency of stationary
phase LSI78Y cells at a concentration range of 5 to 100 nM.
The maximum effect of vasopressin was noted at 100 nM, at
which concentration the cloning efficiency of treated cells was
22.92 Â±2.9% compared to 15.98 Â±0.7% for untreated control
cells.
The effect of dDAVP on the cloning efficiency of exponential
phase P388 leukemia cells was also examined at a dDAVP
concentration range of 5 to 150 nM. A dose-response effect was
observed with maximal augmentation occurring at a dDAVP
concentration of 100 nM, at which the cloning efficiency of
treated cells was 1.84-fold greater than that of untreated control
cells, and this difference was highly significant (P < 0.001).
This observation indicated that the growth-promoting activity
of dDAVP was not restricted to one cell type.
Effect of dDAVP on 1,2- and 1,3-DAG Levels in Murine
LSI78Y Lymphoblasts. The effect of 100 nM dDAVP desmo-
pressin on profiles of 3H-labeled 1,2- and 1,3-DAG in LSI78Y
cells 3 min after treatment is shown in Fig. 1. Markedly higher
peaks for both tritiated 1,2- and 1,3-DAG suggest increased
synthesis of these products after incubation with dDAVP. A
time course of 1,2-[3H]DAG and total 3H-labeled diacylglyc-
erols in control and dDAVP-treated cells is shown in Fig. 2. In
three separate experiments, dDAVP treatment was associated
with increases in tritiated diacylglycerols at 3 and 9 min.
Despite considerable interexperimental variability, randomized
block design analysis of variance showed an interaction between
time and dDAVP effect, and comparisons of tritiated diacyl
glycerols were made between control and dDAVP-treated cells
at each time point. Treatment with dDAVP resulted in a
significant increase of 1,2[3H]DAG at 9 min (P < 0.01) and of
total tritiated diacylglycerols at both 3 min (P < 0.05) and 9
min (P < 0.02) (Fig. 3).
Effect of dDAVP on Inositol Phosphate Levels. The level of
radioactivity in IP, IP2, and IP3 of cells treated with [3H]inositol
was determined in slow growing murine L5178Y cells at 10 s
and after 3 and 9 min after the addition of 100 nM dDAVP
(Fig. 4). Within 10 s of treatment with dDAVP there was a
marked decrease (P< 0.001) in the level of IP3, but subsequently
no change was observed for up to 9 min (Fig. 4A). Whereas in
untreated control cells, IP( content decreased gradually from
zero to 9 min, and this decline, as evaluated by repeated
measures analysis of variance, was statistically significant (P <
0.001). There was a significant reduction (P < 0.02) of IP2 in
both control and dDAVP-treated cells with time; however, no
difference was noted between control and dDAVP-treated cells
(Fig. 4B). The response of IP to dDAVP treatment was similar
to that of IP3, with an initial significant drop (P < 0.01) being
followed by no change for up to 9 min, whereas in control cells,
a significant decline (P < 0.001) of IP was observed over 9 min
(Fig. 4Q.
DISCUSSION
Vasopressin receptors have been found in the kidney, liver,
brain, pituitary, aortic smooth muscle, and on platelets (2), and
two subtypes have been identified. V, receptors mediate pressor
activity and are associated with increased phosphatidylinositol
turnover and formation of IP3 and DAG (14-16). V2 receptors
mediate antidiuretic activity and are associated with activation
of adenylate cyclase to raise cyclic AMP levels (17-20). Roz-
engurt and workers have found vasopressin to be a potent
mitogen for murine Swiss 3T3 cells, acting synergistically with
insulin and several other growth-promoting factors (3); to mod
ulate epidermal growth factor affinity (21); and to induce de-
sensitization to its mitogenic effect in 3T3 cells after prolonged
incubation (22). Additional evidence was provided suggesting
that the growth-promoting activity in 3T3 cells is mediated by
a pressor-type (V]) receptor (22).
dDAVP has a relative affinity for V, receptors of only 0.009
the relative affinity of vasopressin, while having 1.6-fold the
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Table 1 Cloning efficiency of murine L5I87Y lymphoblasts treated with dDA VP
Cells were treated with dDAVP for 10 min as described in the text. In separate experiments, the growth-promoting effect of dDAVP was determined using
stationary phase cells and cells doubling at different rates as described in the text. The cloning efficiency of cells treated with desmopressin is expressed as a percentage
of the cloning efficiency of untreated control cells.
Doubling
time(h)Stationary
262416
1212Control4.3
Â±0.5"
10.8 Â±.222.3
Â±2.138.3
Â±3.1
40.9 Â±3.578.0
Â±4.725
nM
dDAVP7.0
Â±0.3*
7.6 Â±0.627.1
Â±1.427.8
Â±2.8
39.1 Â±.669.9
Â±1.275
nM
dDAVP6.7
Â±0.4C
17.1Â±0.9*19.6
Â±2.436.8
Â±2.9
51.2Â± .774.2
Â±3.9100
nM
dDAVP7.2
Â±0.5C
19.5 Â±2.6/21.3
Â±2.936.0
Â±0.8
43.8 Â±3.479.7
Â±3.0150nM
dDAVP6.0
Â±0.4"
21.0Â±2.0*29.6
Â±2.558.0Â±0.7'
54.9 Â±3.6"75.4
Â±3.6225
nM
dDAVPND'19.3
Â±2.7''NDND
NDND375
nM
dDAVPND
ND23.0
Â±2.539.3
Â±0.6
41.8Â±4.281.0
Â±2.8
" Mean Â±SE of 4 to 12 determinations.
*P < 0.001 (two-tailed t test).
' P < 0.0025 (two-tailed t test).
' P < 0.01 (one-tailed t test).
' ND, not determined.
fP< 0.01 (two-tailed t test).
MOBILITY (CM)
Fig. 1. Tritiated triglycÃ©rides,1,2-[3H]- and 1,3-DAG, and 3H-labeled phos-
pholipids in L5178Y cells in the absence (A) and presence (B) of dDAVP. Cells
were preincubated for 44 h with [3H]arachidonic acid and then treated for 3 min
with either 0.85% NaCl solution as control (A) or 100 nM dDAVP (B). A profile,
based on radioactivity, of lipid migration on a TLC plate was produced by an
imaging scanner. After exposure of the TLC plate to iodine vapor for visualization
of unlabeled standards, the plate was compared to the radioactivity profilo, and
the following radioactive fractions were identified: triglycÃ©ride(Peak 1); 1,3-D AG
(Peak 2); 1,2-DAG (Peak 3); and phospholipid (Peak 4), as illustrated in the
boxes along the abscissa. In subsequent computer analysis, the radioactivity of
each peak, expressed as a percentage of the total radioactivity, was determined.
relative affinity of vasopressin for V2 receptors (23). These
differences are the result of molecular modifications of hemi-
cystine at position 1 and substitution of the D-isomer of arginine
for L-arginine at position 8 (2). Correspondingly, Rozengurt et
al. found that 10 ng/m\ of dDAVP induced the same maximal
stimulation of DNA synthesis as 100 ng/ml of vasopressin in
3T3 cells (21).
In this study, dDAVP did not affect the cytocidal activity of
melphalan in murine LSI78Y lymphoblasts, despite an in
creased influx of melphalan, but significantly augmented the
cloning efficiency of stationary phase or slowly dividing
LSI78Y cells and exponential phase murine P388 leukemia
cells. In addition, there were significant differences between
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Fig. 2. A time course of 1,2-[3H]DAG ( ) and total 3H-labeled diacylglyc-
erols ( ) in control L5178Y cells (O) and in cells treated with 100 nM
dDAVP (â€¢)after 44-h preincubation with ['Hjarachidonic acid. Total |'H]DAG
includes irii until 1,2- and 1,3-DAG, and the data are expressed as a percentage
of the total radioactivity as described in the legend to Fig. 1. Incubations were
terminated by addition of ice-cold DPBS, and centrifugation was at 1000 rpm for
5 min as described in the text.
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Fig. 3. 1,2-[3H]DAG and total JH-labeled diacylglycerols in control LSI 78Y
cells and in cells treated with 100 nM dDAVP for 3 min (O) and for 9 min (â€¢).
Total [3H]DAG includes tritiated 1,2- and 1,3-DAG, and the data are expressed
as a percentage of the total radioactivity as described in the legend to Fig. 1. Each
control point (C) represents one or two determinations, and each treatment point
(dDA VP) represents the mean of two determinations. Analysis of variance showed
a significant difference between control and dDAVP-treated cells for 1,2-[3H)
DAG at 9 min (P < 0.01) and for total 3H-labeled diacylglycerols at 3 min (P <
0.05) and 9 min (P < 0.02).
control and dDAVP-treated cells for tritiated diacylglycerols.
1,2-[3H]DAG production increased after 9-min incubation with
dDAVP, whereas total [3H]DAG was increased after 3 and 9
min, providing evidence that the growth-promoting activity of
dDAVP may be mediated through Vi receptors. Using the TLC
methods which provided for excellent separation of the 1,2-
and 1,3-DAG isomers, we found that production of both iso-
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TIME (MIN)
Fig. 4. Effect of dDAVP on the level of inositol phosphates in L5178Y cells:
IP, (A); IP2 (B): and IP (C). Cells were prelabeled with [3Hlinositol and incubated
with either 100 nM dDAVP in saline (â€¢)or saline alone (O) for various times.
All the values are normalized with respect to the control value at 3 min, which
was set at 100%. Each point is the mean of at least 6 independent determinations.
mers was significantly increased in murine L5178Y lympho-
blasts after 3- and 9-min incubation with desmopressin.
A series of studies by Nishizuka and coworkers has provided
evidence that DAG, a product of the phospholipase C-mediated
hydrolysis of PIP2, initiates the activation of protein kinase C,
resulting in cell proliferation (24). Diacylglycerols containing a
1,2-sn configuration are capable of activating protein kinase C
in rat brain, while two other stereoisomers, 2,3-DAG and 1,3-
DAG, neither activate nor inhibit the enzyme (25). The impor
tance of increased 1,3-DAG production in this setting is un
clear, and this finding requires further investigation. The gen
eration of DAG as a result of receptor-ligand interaction is
classically considered the result of phosphatidylinositol hydrol
ysis by phospholipase C (26, 27). Recently investigators have
reported that DAG may also be produced by hydrolysis of
phosphatidylcholine by a phosphatidylcholine preferring phos
pholipase C (28-30). Grillone et al. (30) have shown that, in
smooth muscle cells A-10, vasopressin induces Vi receptors to
activate both phosphatidylinositol- and phosphatidylcholine-
specific phospholipase C, resulting in the release of arachidonic
acid and the formation of DAG from both sources.
In the present study an apparently paradoxical decrease in
the level of IPj and IP has been observed as a result of treatment
of LSI78Y cells with dDAVP. This reduction in the levels of
inositol phosphates suggests that the increase of DAG content
produced by dDAVP might be primarily from the phosphati
dylcholine source. In addition, increased DAG levels might also
be involved in the breakdown of inositol phosphates by activat
ing phosphatases through the protein kinase C pathway (31,
32). After an initial rapid drop, the level of IP3 in dDAVP-
treated cells did not decline further, suggesting that, during this
time, there may be an increased synthesis of IP3 or possibly
curtailment of phosphatase activation in these cells.
This study does not provide direct evidence for the mecha
nism of action of dDAVP; however, the increased cloning
efficiency may represent interaction of dDAVP with Vi recep
tors triggering hydrolysis of both PIP2 and phosphatidylcholine
with increased production of DAG. Increased production of
DAG may in turn initiate activation of protein kinase C, thereby
resulting in cell proliferation. The mitogenic activity of
dDAVP, a nonpeptide of low molecular weight, is particularly
intriguing since most of the known growth factors are much
larger compounds (33). This and other structural analogues of
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vasopressin may be used to study the regulation of cell prolif
eration and to characterize further receptor-ligand interactions.
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